David Ricks, the CEO of Mounjaro and Zepbound maker Eli Lilly, explained why these medications are so expensive on the "In Good Company with Nicolai Tangen" podcast this week. 1. Time and money ...
Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United ...
Of course, Lilly's most important new products are diabetes treatment Mounjaro and weight management medicine Zepbound, which share the active ingredient tirzepatide. In 2024, Eli Lilly's ...
Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are transforming the company. Lilly now has an obligation to take on other challenging diseases like Alzheimer's, ALS and chronic pain, said the ...
Much of Eli Lilly’s recent investments have been focused on meeting the ballooning demand for its blockbuster diabetes and weight loss medications Mounjaro and Zepbound, part of a new class of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback